High-effect MS meds: small short boosts in thinking

Credibility

Interest

Share:2 min read

Key Takeaway

High‑effect MS drugs may give a small early boost in thinking speed, but this benefit is not clearly lasting over time.

What They Found

Researchers looked at how thinking speed changed over time in people with relapsing MS who were taking different disease‑modifying therapies (DMTs), which are medicines meant to slow MS. They measured thinking speed with the Symbol Digit Modalities Test (SDMT), a short test where you match symbols to numbers — like a simple code‑breaking game that times how fast you think. People who started higher‑efficacy DMTs had a noticeable rise in SDMT scores in the first few years, while those on older “platform” therapies changed less. By years three and four the difference between groups was about 2 points on the SDMT, but that gap did not last in later years. Differences between specific medicines (for example anti‑CD20 drugs versus natalizumab) showed small early gains or drops, but overall the results did not show a clear, lasting advantage for higher‑effect drugs on thinking speed.

Who Should Care and Why

People with MS and their caregivers should know that some stronger MS drugs might give a small short‑term boost in processing speed, which could feel like thinking a little quicker or being slightly sharper for everyday tasks. This could matter for things like following conversations, reading mail, or doing timed activities, but the benefit may fade over time, so it should not be the only reason to choose a medicine. Neurologists and MS nurses can use this information when talking with patients about what to expect from different treatments, adding cognition to other factors like relapse prevention and side effects. Caregivers can monitor whether a person seems to think faster or slower after starting a new drug and tell the care team, much like tracking reaction to any new medication. Overall, the findings help set realistic expectations: some early improvement is possible, but long‑term thinking changes are uncertain.

Important Considerations

The study used real‑world registry data, which can include people who are different in health and age, so results may be affected by who was chosen for each drug. Repeating the same thinking test can make people better just from practice, and when researchers adjusted for this the early gains were smaller, so some of the benefit may be from learning the test. The study does not prove that one drug causes lasting changes in thinking speed, so treatment choices should still be based on overall benefits and risks discussed with your care team.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates MS Progression Clinical Trials

Article Topics:

Multiple sclerosiscognitive functiondisease-modifying therapylongitudinal studyprocessing speed

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News